Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 3/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30864167 | 0.89 | NPC1 (0.35) | NPC1 | |
| SCHEMBL16337243 | 0.89 | NPC1 (0.37) | NPC1DRD1MAPT | |
| SCHEMBL16334924 | 0.89 | NPC1 (0.35) | NPC1 | |
| SCHEMBL20610856 | 0.88 | CRHR1 (0.38) | NPC1DRD1CRHR1DGAT1 | |
| SCHEMBL16363024 | 0.85 | KDM4E (0.35) | NPC1DRD1HPGDALDH1A1 | |
| SCHEMBL30362407 | 0.84 | NPC1 (0.36) | NPC1DRD1 | |
| SCHEMBL16338010 | 0.84 | NPC1 (0.36) | NPC1DRD1 | |
| SCHEMBL16337404 | 0.82 | DGAT1 (0.41) | NPC1HPGDALDH1A1DGAT1L3MBTL1 | |
| SCHEMBL16336781 | 0.82 | DRD1 (0.35) | NPC1DRD1DGAT1 | |
| SCHEMBL16337072 | 0.78 | DRD1 (0.57) | NPC1DRD1ALDH1A1DGAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283407-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, SNCA | NPC1 840/4885DRD1 2/4885CRHR1 300/4885 |
| US-11014909-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, SNCA | NPC1 840/4885DRD1 2/4885CRHR1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.